Mayo Clinic Laboratory and Pathology Research Roundup: July 4

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.


Featured Study of the Week

Liver Cancer Patients May See Better Outcomes with Advancements in Personalized Drug Therapies

HepatocellularCarcinoma-960x540Hepatocellular carcinoma (HCC) is a global problem and the second most common cause of cancer-related deaths in the world. Its global incidence has been reported to be on the rise and is predicted to exceed one million cases per year by 2025. In a recent review, published in the Journal of Hepatology, Mayo Clinic researchers examined the clinical implications of current basic research in HCC. Currently, the overall survival of patients with HCC is bleak: less than 15% will live more than five years. This is largely due to the fact that a majority of HCCs are diagnosed at advanced stages when patients are not eligible for curative therapies such as resection or transplantation. And, advanced HCCs are resistant to most standard chemotherapy regimens.


Published to PubMed This Week

brentwestra

Brent Westra

Brent Westra is a Marketing Segment Manager at Mayo Medical Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.